Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
Sept-end listing deadline looms large for Tata Sons
29/09/2025
Two-thirds of Nifty 500 stocks trade below last year’s levels
29/09/2025
Will India-US tariff deal spark the next rally on Dalal Street ?
29/09/2025
IPO boom defies market slump, mobilises nearly Rs 1.7 lakh crore in a year
29/09/2025
Laser Power & Infra, Indo MIM files draft papers with Sebi for IPOs
28/09/2025
Ahead of Market : 10 things that will decide stock market action on Monday
28/09/2025
